Imperial Innovations Group Regulatory News (IVO)

London, UK, 13 March 2015

Edison issues research on Imperial Innovations

The investment case for Imperial Innovations rests in the potential to unlock hidden value from within its portfolio of 95 companies, which span healthcare (therapeutic/medtech), engineering/materials and ICT/digital. Healthcare currently accounts for c 70% of the portfolio value (£252m at 31 July 2014), although Innovations' management plans a rebalance to c 60% healthcare and c 40% technology (engineering/materials and ICT/digital). In this special report we highlight the potential within the technology portfolio, profiling seven companies that could add substantial value over the next few years, above their relatively modest carrying values.

For the full report see:

http://www.edisoninvestmentresearch.com/research/report/imperial-innovations21 

http://www.rns-pdf.londonstockexchange.com/rns/3834H_-2015-3-13.pdf

All reports published by Edison are available to download free of charge from its website.

www.edisoninvestmentresearch.com

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison on: